← All trials
NCT01124253
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2007
- Primary completion
- Oct 1, 2009
- Completion date
- Oct 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 250
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Jiao Tong UniversityLead sponsor
- Simcere Pharmaceutical Co., LtdCollaborator
- Jiao Tong UniversityCollaborator
- Shanghai Municipal Science and Technology CommissionCollaborator
- Jiao Tong UniversityStudy director
- Jiao Tong UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.